Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 2.5% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 2.5% during mid-day trading on Thursday . The stock traded as low as $22.05 and last traded at $22.32. 6,067 shares changed hands during trading, a decline of 97% from the average session volume of 204,738 shares. The stock had previously closed at $22.90.

Wall Street Analysts Forecast Growth

DNTH has been the subject of a number of research reports. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Oppenheimer increased their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. TD Cowen initiated coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Stock Performance

The business’s 50 day moving average is $25.45 and its 200-day moving average is $26.68. The stock has a market cap of $677.18 million, a price-to-earnings ratio of -9.15 and a beta of 1.75.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC grew its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. Fred Alger Management LLC raised its holdings in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after acquiring an additional 4,506 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after purchasing an additional 7,854 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after buying an additional 8,473 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.